Idiopathic hypereosinophilic syndromes (HES) comprise a spectrum of indolent to aggressive diseases characterized by persistent hypereosinophilia. Hypereosinophilia can result from the presence of a defect in the hematopoietic stem cell giving rise to eosinophilia, it can be present in many myeloproliferative disorders or alternatively it may be a reactive form, secondary to many clinical conditions. The hybrid gene FIP1L1-PDGRFa was identified in a subset of patients presenting with HES or chronic eosinophilic leukemia (CEL). In spite of this, the majority of HES patients do not present detectable molecular lesions and for many of them the diagnosis is based on exclusion criteria and sometimes it remains doubt. In this study we explored the possibility to distinguish between HES/ CEL and reactive hypereosinophilia based on WT1 transcript amount. For this purpose, 312 patients with hypereosinophilia were characterized at the molecular and cytogenetic level and analyzed for WT1 expression at diagnosis and during follow-up. This study clearly demonstrates that WT1 quantitative assessment allows to discriminate between HES/CEL and reactive eosinophilia and represents a useful tool for disease monitoring especially in the patients lacking a marker of clonality.
Introduction
Hypereosinophilia is a common biological finding, arising in a number of different clinical situations. 1 Accumulation of eosinophils in peripheral blood (PB) and tissues can result from the presence of a defect in the hematopoietic stem cell giving rise to eosinophilia 2 or, alternatively, hypereosinophilia can accompany the expansion of other members of the myeloid lineage in the setting of a given myeloproliferative disorder. 3 In this case, the eosinophilia appears to be part of the leukemic clone. In addition, malignant cells producing granulocytemacrophage colony-stimulating factor (GM-CSF), IL-3 and/or IL-5 are responsible for hypereosinophilia in Hodgkin's lymphoma and Sezary syndrome. 4 In secondary hypereosinophilia, the myeloid lineage is normal and eosinophil accumulation is a cytokine-driven process. Eosinophils are derived from myeloid progenitors in bone marrow (BM) mainly through the action of three hematopoietic cytokines: IL-3, IL-5 and GM-CSF. 3 Overproduction of one of these cytokines, mainly IL-5, is sufficient to induce blood and tissue eosinophilia by stimulating BM generation. 5 The striking clinical heterogeneity of patients with hypereosinophilic syndrome (HES) strongly suggests pathogenic diversity. The existence of a myeloproliferative variant of hypereosinophilia was suggested many years ago, by the evidence of eosinophil clonality. 6, 7 More recently, Cools et al. 8 described a new molecular defect which characterizes a subset of patients presenting with HES/chronic eosinophilic leukaemia (CEL). This genetic abnormality is represented by the presence of a fusion gene FIP1L1-PDGFRa coding for a tyrosine kinase protein constitutively activated. This hybrid transcript represents not only a molecular marker of HES but it offers the basis for a molecular targeted therapy with imatinib. [9] [10] [11] [12] [13] In spite of this, in most patients with eosinophilia, no molecular lesions can be detected and the majority of them exhibit a normal karyotype by conventional cytogenetic, with only sporadic cases with clonal chromosomal abnormalities.
14 So far, for the majority of them, the diagnosis of HES is based on exclusion criteria 15 and in same cases it may remain doubt. The Wilms tumor gene (WT1) codes for a zinc-finger transcription factor expressed in few normal adult tissues including BM and PB cells. 16 By contrast, it is overexpressed in many types of hematopoietic disorders including acute and chronic leukemias and myeloproliferative disorders. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] At present, the quantitative assessment of WT1 transcript has been widely accepted as a useful tool for monitoring the presence of the reappearance of the leukemic clone in many hematological malignancies. [20] [21] [22] [23] [24] WT1 is, therefore, a molecular marker useful not only to monitor minimal residual disease in acute and chronic leukemias, but also represents a powerful tool for the detection of clonal myeloid disorders, which sometimes require a differential diagnosis from secondary or reactive conditions. In this study, the quantitative assessment of WT1 transcript amount has been evaluated as a marker of eosinophilia related to HES or CEL.
Materials and methods

Patients
Between January 2001 and June 2005, 312 patients affected by hypereosinophilia were enrolled in the present prospective study. Moreover 70 PB and 50 BM samples collected from healthy subjects were studied as control. Ninety patients (28.8%) were diagnosed as HES (52 cases) or CEL (48 cases). The diagnosis of HES was established following the WHO criteria. 25 HES was defined as a PB eosinophilia greater than 1500 cells/ml for longer than 6 months, absence of any apparent etiologies for eosinophilia, 1-3 exclusion of malignancies in which eosinophilia is reactive or part of the neoplastic clone and of T-cell disorders associated with abnormalities of immunophenotype and cytokine production with or without evidence of lymphocyte clonality. CEL was distinguished by HES by the presence of clonal cytogenetic or molecular abnormalities. The clinical data of HES/CEL patients are summarized in Table 1 . In 222 patients (71.2%) clinical and/or laboratory findings were consistent with other eosinophilic disorders, including Churg-Strauss vasculitis, chronic eosinophilic pneumonia, allergic gastroenteritis, parasitosis and allergic diseases, each of them defined by established diagnostic criteria. The clinical data are summarized in Table 2 . All the patients, following written informed consent according to local Ethical Commitment-approved guidelines, were submitted to molecular analysis.
The median age of the 222 patients affected by reactive eosinophilia was 47714 years (range 20-77), 211 were females and 101 were males. The mean number of white blood cells (WBC) was 980072987 ml (range 5500-21900) and the mean number of eosinophils was 19097432 ml (range 1500-4800). Thirsty-sis percent of the patients affected by reactive conditions presented with organ involvement.
The median age of HES/CEL patients was 48.3715 years (range 20-78), the mean number of WBC was 19692715141 ml (range 5300-85000) and the mean number of eosinophils was 783775575 mm 3 (range 1595-2 8750). In 232 out of 312 cases both BM and PB samples were collected at diagnosis. In the remaining 80 cases only BM or PB were studied (52 PB samples and 28 BM samples). In HES patients treated with imatinib (73 out of 90) or with other conventional therapies including hydroxiurea (four patients) or interferon-a (IFN-a) (eight patients) the BM and PB samples were analyzed at regular time intervals during treatment (after 1, 3, 6, 12 months and then every 6 months).
Cytogenetic studies
Conventional cytogenetic studies were performed with standard banding techniques. The minimum number of marrow cell metaphases analyzed was 20.
FISH analysis
Fluorescence in situ hybridization (FISH) analysis was performed using the commercially available double fusion signal D-FISH BCR/ABL probe (Oncor, Appligene, Gaithersburg, MD, USA) to exclude the involvement of the BCR and ABL genes. The 8p11 breakpoint was investigated using a bacterial artificial chromosomes (BAC) bK350N15 spanning the FGFR1 gene, kindly provided by Dr Negrini (University of Ferrara, Italy). BAC probes for the 4q12/PDGF-alpha (RP11-231C18), 5q33.1/ PDGF-beta (RP11-368O19) and 4q12/CHIC2 (RP11-367N1) respectively were provided by Mariano Rocchi (University of Bari, Italy). BAC DNA was isolated from cultures using a standard miniprep procedure and labeled with biotin by Nick translation. FISH analysis was performed on a Nikon fluorescence microscope (Eclipse E1000, Nikon Instruments, Nikon Corporation, Tokyo, Japan).
Molecular studies
Unfractioned BM and/or PB samples were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) for Table 1 Continued RT-PCR was routinely performed at baseline, and in the positive cases during follow-up. RNA extraction was performed according to standard methods. The RT reaction conditions were adapted from the BIOMED-1 protocol. 26 The RT-PCR reaction for the detection of FIP1L1-PDGFRa fusion transcript was carried out as described by Cools et al. 8 Briefly, fusion of FIP1L1 to PDGFRa was analyzed by nested polymerase chain reaction (PCR) using primers FIP1L1-F1 (5 0 -acctggtgctgatctttctgat) and PDGFRa-R1 (5 0 -tgagagcttgttttt cactgga) during the first PCR, and primers FIP1L1-F2 (5 0 -aaaga ggatacgaatgggacttg) and PDGFRa-R2 (5 0 -gggaccggcttaatccatag) for the second PCR step.
Real-Time Quantitative RT-PCR (RQ-PCR) analysis for WT1
RQ-PCR reactions and fluorescence measurements were made on the ABI PRISM 7700 Sequence Detection System (PE Applied Byosystems, Foster City, CA, USA) as described. 27 Briefly, the RQ-PCR primers and probe for WT1 were 5 0 -CAGGCTGCAATAAGAGATATTTTAAGCT-3
The RQ-PCR primers and probe for ABL were 5 0 -TGGAGATAACACTCTAAGCATAACTAAAGGT-3
The analysis was performed in triplicate and the results showing a discrepancy 41 Ct in one of the wells were excluded and repeated.
For quantitative assessment of WT1, a calibration curve with a plasmid containing the WT1 target sequence was used (Amplimedical s.p.a. Bioline Division, Turin, Italy). The sensitivity of the RQ-PCR assay for WT1 was established as described. 21 The WT1 values obtained by RQ-PCR were normalized with respect to the number of ABL transcripts and expressed as WT1 copy number every 10 4 copies of ABL.
Results
Cytogenetic and molecular analysis
CEL patients (34 out of 48) were characterized by the presence of the fusion transcript FIP1L1-PDGFRa and in 62% of the cases (21 out of 34 patients) by the deletion of CHIC2 gene detected by interphase FISH analysis. All of them were males. The remaining 14 patients showed clonal cytogenetic alterations, many of them previously reported as associated with the presence of HES or CEL. 28 In details, one was characterized by the þ 17q abnormality, one by the trisomy of chromosome 4, one by trisomy of chromosome 8, one by the translocation t(1;15), two by the translocation t(5;12) and the corresponding fusion transcript TEL-PDGFRb, one by t(2;4) (p24;q12), one by the deletion of Y chromosome and six were characterized by the presence of a cytogenetic marker. Many of these abnormalities such as t(2;4) (p24;q12), 29 32 For other cytogenetic abnormalities, there is no evidence of a direct relationship with the development of hypereosinophilia, we can consider the presence of a clonality marker and the absence of any other hematopoietic disorders associated with eosinophilia as suggestive for the 
WT1 quantitative assessment
As previously reported in other papers, BM and PB samples obtained from healthy volunteers express very low levels of WT1. 18, 20 In our hands, the majority of normal PB are negative for WT1 expression and the mean value in positive samples is 473 WT1 copies/10 4 ABL copies (median ¼ 0, range 0-20). BM samples of normal donors express a mean value of WT1 copies of 32719 (median ¼ 28, range 0-90). In both BM and PB samples obtained from patients with established reactive eosinophilia the expression levels of WT1 are similar to those detected in healthy controls with a mean value in BM of 31.5718 (median ¼ 26.5, range 0-78) and 1.872.9 (median ¼ 0, range 0-12) in PB. These values are not statistically different from those obtained in normal subjects (P value ¼ 0.86 in BM and P ¼ 0.74 in PB by t-test). By contrast, HES/CEL patients show increased values in both BM and PB when compared to healthy subject and to reactive hypereosinophilia ( Figure 1) . CEL patients showed a mean number of WT1 copies/ 10 4 ABL copies of 6117667 (median ¼ 440, range 77-633) in BM and 1487125 (median ¼ 108, range 20-679) in PB. These values are highly significant when compared to healthy subjects or to reactive hypereosinophilia (Po0.0001 in both BM and PB as compared to reactive forms of eosinophilia and to healthy subjects).
As shown in Table 1 , among CEL patients, the cases characterized by the presence of the fusion transcript FIP1L1-PDGFRa show similar WT1 values as compared to CEL patients with other cytogenetic alterations (P ¼ 0.58 for BM and 0.66 for PB). Finally, the group of HES patients without any evidence of clonality but fulfilling the criteria of HES showed a mean value of WT1 of 6387333 (median ¼ 624, range 190-1348) in BM and 1677153 (median ¼ 102, range 39-691) in PB. Again, these values are significantly different when compared to reactive hypereosinophilia and healthy subjects (Po0.0001 in both BM and PB) but not as compared to CEL (P ¼ 0.8 for BM and P ¼ 0.52 for PB). Only one case out of 90 HES/CEL showed WT1 expression within the normal range in both BM and PB. In particular, this patient was characterized by the presence of the fusion transcript FIP1L1-PDGFRa (unidentified progressive number (UPN) 34 in Table 1 ). If we consider separately the HES patients with organ involvement and those without, we found similar WT1 values within the two groups. In particular, we found a mean value of 61373451 WT1 copies/10 4 ABL copies in those with organ involvement and 6537333 WT1 copies/10 4 ABL copies in those without (P value of 0.71 between the two groups). By contrast, both groups individually compared to normal subject or to reactive conditions were highly significant (Po0.0001 in both cases).
Finally, we examined the correlation between the WT1 values in PB and BM samples of HES/CEL patients. As shown in Figure 2 , regression analysis demonstrated a significant correlation between the two variables resulting in an r value of 0.73.
WT1 evaluation during follow-up
All the 34 patients characterized by the presence of the specific marker FIP1L1-PDGFRa treated with imatinib according to the Italian protocol established by the GIMEMA Working Party on Chronic Myeloid Leukemia (CML), four patients with normal karyotype treated with the same protocol and four cases characterized by clonal cytogenetic markers treated with IFNa, were analyzed by RT-PCR for the detection of the fusion transcript, by cytogenetic analysis and by RQ-PCR for the quantification of WT1 expression during follow-up.
As shown in Figure 3 , the analysis of WT1 in FIP1L1-PDGFRapositive patients during imatinib treatment showed a progressive reduction in WT1 expression levels, which parallels the behavior of the specific transcript. WT1 returned within the normal range of expression according to a negative PCR for FIP1L1-PDGFRa. The mean value of WT1 after 3 months of therapy was 48.9727 copies/10 4 ABL copies (median ¼ 45, range 10-139). Only two patients did not reach the PCR negativity for FIP1L1-PDGFRa transcript (defined as the disappearance of the transcript after nested PCR) after 3 months of therapy and both presented WT1 values above the normal range (120 and 139, respectively). One patient, after reaching the molecular remission during imatinib treatment, underwent a hematological and molecular relapse. As shown in Figures 3 and  4 , WT1 and the specific transcript increased in parallel. Similar results were obtained in patients characterized by the presence of a cytogenetic marker treated with IFN-a. As shown in Figure 5 , WT1 transcript showed a progressive reduction and returned within the normal range in accordance to the achievement of a normal karyotype. Finally, in seven patients with normal karyotype treated with imatinib without any evidence of hematological response, the evaluation of WT1 transcript amount revealed high values during the entire course of the disease.
Discussion
It is notoriously difficult to distinguish between HES and the reactive forms of hypereosinophilia, especially in the cases lacking the fusion gene FIP1L1-PDGFRa, or negative for the presence of clonal cytogentic aberrations. We now know, however, that many hypereosinophilic cases without obvious chromosomal abnormalities are clonal in origin, 6, 7 further illustrating the difficulty in distinguishing HES and CEL and the need for new molecular markers to establish clonality. One method for establishing a diagnosis of CEL is the demonstration of eosinophils clonality, which, however, is frequently difficult to obtain. X chromosome inactivation-based assessment of clonality is of limited value in HES because most patients are males. There are increasing evidences that the identification of the patients affected by HES/CEL is of primary importance as a correct therapy may change the natural history of the disease. [8] [9] [10] [11] At present only a percentage of hypereosinophilic patients fulfilling the established WHO criteria for the diagnosis of HES is characterized by the presence of a molecular or cytogenetic marker. [8] [9] [10] [11] The discovery of the hybrid gene FIP1L1-PDGFRa was revolutionary from a therapeutic point of view, as it offers the basis for a molecular targeted therapy with imatinib with impressive clinical results. [8] [9] [10] [11] [12] In spite of these, several responses to different agents, for example IFN-a, have been reported in patients without the involvement of PDGFR.
15
In this study we provide evidence that WT1 quantitative assessment is a powerful molecular marker able to distinguish between HES/CEL and the reactive forms of eosinophilia.
WT1 is a tumor-suppressor gene coding for a zinc-finger transcription factor located on chromosome 11p13, which was originally identified for its involvement in the pathogenesis of the Wilms' tumor. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 34 WT1 is expressed in a variety of tissues including ovary, testis and spleen. In normal BM, WT1 expression is low and even lower in normal PB where in a percentage of cases, it is undetectable even by RT-PCR and RQ-PCR. 20, 35 By contrast, WT1 expression has been described to be highly increased in most cases of acute myeloid and lymphoid leukemia, [17] [18] [19] [20] in CML, 23 myelodysplastic syndromes, 18, 36 and also in acquired hematological diseases like paroxysmal nocturnal hemoglobinuria. 37 In this prospective study, using a sensitive RQ-PCR approach, we have analyzed WT1 expression in a large series of HES/CEL and secondary hypereosinophilic patients from whom all the essential data to establish a correct Figure 4 Evaluation of WT1 transcript amount during follow-up of a FIP1L1-PDGFRa-positive patients treated with imatinib. After 3 months of therapy the patients achieved a complete molecular response; FIP1L1-PDGFRa was negative and WT1 returned within the normal range. After the suspension of treatment the patient returned positive and WT1 increased in parallel. The treatment was restarted and after 6 months of follow-up the patient was negative for the fusion transcript and WT1 was within the normal range. The black dots indicate the negativity for FIP1L1-PDGFRa, the red dots, the positivity. Figure 5 Evaluation of WT1 transcript amount during the follow-up of HES patients characterized by the presence of a cytogenetic marker treated with IFN-a. WT1 transcript was above the normal range in both BM (red dots) and PB (blue dots) in accordance with the presence of a cytogenetic marker during the first year of follow-up while on steroid therapy. Then the patient started alphaIFN therapy and after 6 months the patient achieved the complete cytogenetic response and, in parallel, WT1 returned within the normal range in both BM and PB. CY R, complete cytogenetic response. IFN therapy, Starting point of IFN treatment.
WT1 quantitative assessment in HES D Cilloni et al diagnosis were available. The data obtained show that in the large majority of HES/CEL, including those characterized by the presence of the fusion gene FIP1L1-PDGFRa, WT1 is expressed above the range observed in normal controls and in secondary reactive hypereosinophilia in both BM and PB. Moreover, our paper confirms that a longitudinal monitoring of the WT1 levels may represent a good marker to establish disease progression or response to therapy. The implications of these findings in clinical practice are obvious as the identification of a molecular marker able to distinguish between the presence of HES/CEL and a reactive disorder can be of great help in decision-making for hypereosinophilic patients. Moreover, the fact that WT1 may be abnormally expressed even in the PB of HES patients can facilitate a correct diagnosis and it allows a more strict followup. In conclusion, our study demonstrates that the expression level of WT1 potentially fulfills all the requirements to be introduced as an additional marker to the standard parameters so far considered in the diagnosis of HES, particularly useful in the cases in which standard molecular and cytogenetic analyses are not informative. For this purpose, although new quantitative real-time procedures promise to simplify the protocols for WT1 transcript quantitative assessment that are currently in use, standardization and the introduction of rigorous, internationally accepted controls are ongoing to enable RQ-PCR to become a robust and routine basis for diagnostic purposes.
